scholarly journals Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder

2021 ◽  
Vol Volume 17 ◽  
pp. 1047-1053
Author(s):  
Mizue Ichinose ◽  
Itaru Miura ◽  
Sho Horikoshi ◽  
Shinnosuke Yamamoto ◽  
Keiko Kanno-Nozaki ◽  
...  
Keyword(s):  
Side Effects ◽  
Schizoaffective Disorder ◽  
Homovanillic Acid

Clomipramine (Anafranil) in the Treatment of Cataplexy

1973 ◽  
Vol 1 (5) ◽  
pp. 427-431 ◽  
Author(s):  
J D Parkes
Keyword(s):  
Side Effects ◽  
Inborn Error ◽  
Homovanillic Acid ◽  
Considerable Increase ◽  
Cerebral Metabolism ◽  
Inborn Error Of Metabolism ◽  
Familial Occurrence ◽  
One Year

Seven patients with narcolepsy and cataplexy were treated with clomipramine. This abolished cataplexy in three patients and resulted in a reduction in the frequency of attacks in the others. Tolerance to clomipramine did not develop and treatment remained effective over a one-year period. One patient had a considerable increase in weight but no other side-effects of clomipramine occurred. Clomipramine had no action on narcolepsy but given together with amphetamines resulted in a reduction in the amphetamine dosage required to control narcolepsy. The life-long nature, familial occurrence and absence of specific pathology in the narcoleptic syndrome is consistent with an inborn error of metabolism. The concentration of homovanillic acid in the CSF of six patients with narcolepsy was approximately half normal. One of these patients had not been treated with amphetamines. This finding could be explained by a reduced cerebral metabolism of catecholamines in the narcoleptic syndrome.

Oxcarbazepine in Mood Disorders

2001 ◽  
Vol 36 (12) ◽  
pp. 1254-1256 ◽  
Author(s):  
John Norton
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Mood Disorders ◽  
Schizoaffective Disorder ◽  
Rapid Cycling ◽  
Bipolar Illness ◽  
Mixed Responses

Patients with bipolar illness or schizoaffective disorder–manic type can present with a variety of symptoms and have mixed responses to treatment. This is especially true for patients who have rapid cycling or mixed bipolar illness. The following cases describe the use of oxcarbazepine in patients with either bipolar illness or schizoaffective disorder. This agent, an analogue of carbamazepine, has fewer drug–drug interactions and side effects and thus may prove to be a better tolerated agent in the treatment of these very serious illnesses. A discussion of the properties of oxcarbazepine is also included.

Clinical observation of 11 patients under clozapine-lithium association

1993 ◽  
Vol 8 (4) ◽  
pp. 213-218 ◽  
Author(s):  
C Bryois ◽  
F Ferrero
Keyword(s):  
Side Effects ◽  
Mood Disorders ◽  
Schizoaffective Disorder ◽  
Aggressive Behaviour ◽  
Psychotic Disorders ◽  
Clinical Observation ◽  
Lithium Treatment ◽  
Lithium Sulfate ◽  
Plasmatic Level ◽  
The Mean

SummaryTen men and one woman aged 27 to 52 years and presenting chronic evolution of their psychotic disorders benefited from a treatment which associated lithium sulfate at a plasmatic level of 0.5 to 0.8 meq/L with clozapine (mean posology: 300 mg/day). Five patients presented chronic disorganized schizophrenia (295.14), five a schizoaffective disorder (295.70) and one patient chronic undifferentiated schizophrenia (295.94) according to DSM III-R. Nine of the eleven patients showed mood disorders in addition to their psychotic and dissociative symptomatology. The remaining two presented chronic disorganised schizophrenia with aggressive behaviour. The clozapine-lithium association led to stabilization and improvement in the condition of all patients. Nine patients are still undergoing treatment with satisfactory results. The mean duration of the clozapine-lithium treatment, which has proved to be well tolerated with regard to side-effects, is about five years.

The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder

2017 ◽  
Vol 72 (2) ◽  
pp. 124-129 ◽  
Author(s):  
Dragana Ignjatović Ristić ◽  
Dan Cohen ◽  
Andrea Obradović ◽  
Katarina Nikić-Đuričić ◽  
Marija Drašković ◽  
...  
Keyword(s):  
Side Effects ◽  
Schizoaffective Disorder ◽  
Antipsychotic Side Effects

Cerebrospinal fluid homovanillic acid and hypokinetic side effects of neuroleptics

1985 ◽  
Vol 85 (2) ◽  
pp. 184-186 ◽  
Author(s):  
Malcolm B. Bowers
Keyword(s):  
Cerebrospinal Fluid ◽  
Side Effects ◽  
Homovanillic Acid

Is There Evidence That Stimulus Parameters and Electrode Placement Affect the Cognitive Side Effects of Electroconvulsive Therapy in Patients With Schizophrenia and Schizoaffective Disorder?

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mustafa Cicek ◽  
William V. McCall ◽  
Zhixing Yao ◽  
Harold A. Sackeim ◽  
Peter Rosenquist ◽  
...  
Keyword(s):  
Side Effects ◽  
Electroconvulsive Therapy ◽  
Schizoaffective Disorder ◽  
Electrode Placement ◽  
Stimulus Parameters ◽  
Cognitive Side Effects

The nucleus accumbens–possible site of antipsychotic action of neuroleptic drugs?

1977 ◽  
Vol 7 (2) ◽  
pp. 213-221 ◽  
Author(s):  
T. J. Crow ◽  
J. F. W. Deakin ◽  
A. Longden
Keyword(s):  
Nucleus Accumbens ◽  
Side Effects ◽  
Homovanillic Acid ◽  
Rank Order ◽  
Dopamine Turnover ◽  
Therapeutic Effects ◽  
Receptor Blockade ◽  
Neuroleptic Drugs ◽  
Extrapyramidal Side Effects ◽  
Dopaminergic Transmission

synopsisThe hypothesis that neuroleptic drugs exert their therapeutic effects by blocking dopaminergic transmission has been investigated by examining the effects of 3 neuroleptic drugs on dopamine turnover in 2 dopaminergically innervated regions of brain – the neostriatum and nucleus accumbens. The drugs chlorpromazine, thioridazine and fluphenazine, known to be therapeutically active in the treatment of schizophrenia, but to have differing incidences of extrapyramidal side effects, were administered to rats in dose ratios approximating to those effective in man. All 3 drugs induced a similar rise in the content of the dopamine metabolite homovanillic acid (HVA) in the nucleus accumbens, whilst the changes in HVA observed in the neostriatum were in the rank order in which these drugs produce extrapyramidal side effects. While the concentrations of dopamine metabolites in the frontal cortex were too low to assess the possibility that neuroleptic drugs have actions at this level, our results are consistent with the hypothesis that these drugs exert their therapeutic effects by dopamine receptor blockade in the nucleus accumbens.

Persistent cerebellar deterioration in a patient with lobar pneumonia under lithium, carbamazepine, and trifluperidol treatment

1999 ◽  
Vol 14 (3) ◽  
pp. 175-176 ◽  
Author(s):  
F Bischof ◽  
A Melms ◽  
M Fetter
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Therapeutic Range ◽  
Schizoaffective Disorder ◽  
Lithium Toxicity ◽  
Lithium Level ◽  
Serum Lithium Level ◽  
Lobar Pneumonia

SummaryWe report on a patient with schizoaffective disorder who was on combination therapy of lithium, carbamazepine, and the neuroleptic trifluperidol. He experienced a lobar pneumonia and developed an acute and persistent cerebellar deterioration which was most likely due to lithium toxicity, while the serum lithium level was within the therapeutic range. The combination of lithium, carbamazepine, and neuroleptics is common, and is generally considered to be safe. The reported case suggests that this regimen might increase the risk of intoxication with potentially disabling side-effects.

Sign in / Sign up

Export Citation Format

Share Document